# Gareth Asten

> Gareth Asten is a Series A investor at Acre Venture Partners backing Health Care and Biotechnology. See 9 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Acre Venture Partners](https://shizune.co/investors/profile/acre-venture-partners)
- Location: Los Angeles, United States
- Total investments: 9
- Last investment: Dec 2024
- Lead investor: 44%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/gareth-asten-5709801ab

Gareth Asten is a Co-Founder and Managing Partner at Acre Venture Partners.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 4 | 44% |
| Biotechnology | 3 | 33% |
| Food and Beverage | 3 | 33% |
| DIY | 1 | 11% |
| AgTech | 1 | 11% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 33% |
| Series C | 2 | 22% |
| Pre-Seed | 1 | 11% |
| Series B | 1 | 11% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| one.bio | BCD Bioscience is an emerging biotechnology spinout from UC Davis that creates ingredients for food and biopharmaceutical applications. The company was founded in 2019 and is headquartered in Davis, California, United States. | $27M | Series A | Dec 12, 2024 |  |
| Switch Bioworks | Switch Bioworks produces sustainable nitrogen fertilizer by reprogramming naturally occurring symbiotic microbes to produce fertilizers. | $4.3M | Pre-Seed | May 25, 2022 |  |
| one.bio | BCD Bioscience is an emerging biotechnology spinout from UC Davis that creates ingredients for food and biopharmaceutical applications. The company was founded in 2019 and is headquartered in Davis, California, United States. | $12M | Series A | Apr 13, 2022 |  |
| Supergut | UR Labs is a consumer health and food tech company that focuses on nutrition solutions to address chronic health conditions. The company’s first product line launched in May 2020 and started with a meal replacement shake. It is named Muniq in honor of Washington’s late sister, Monica, who suffered from diabetes and chronic illnesses. Sincelaunching Muniq in May, UR Labs has experienced quicker traction than anticipated, not only financially, but in feedback from consumers that are using the products regularly. Next up, the company is working on new applications for its products, such as controlling blood sugar and weight. | $8.2M | Series A | Jan 12, 2021 |  |
| one.bio | BCD Bioscience is an emerging biotechnology spinout from UC Davis that creates ingredients for food and biopharmaceutical applications. The company was founded in 2019 and is headquartered in Davis, California, United States. | $5M | Series A | May 13, 2020 |  |
| Evolve Biosystems | Evolve Biosystems is a biotechnology company that specializes in providing microbiome-based products designed to develop, restore, and maintain. The company's platform focuses on solving the gut dysbiosis throughout the human life cycle as well as in various animal species, enabling physicians to maintain the healthy gut microbiome in newborninfants with a consumer-directed home use product, and a hospital-based neonatal ICU product. | $40M | Series C | Jun 13, 2018 |  |
| The Safe + Fair Food Company | The Safe + Fair Food Company is a plant-based food company that produces healthy foods for friends, communities, and family. The company's products help expand comfort and ease for food-allergic families and grow inclusive communities that come together with a shared love of food. The Safe + Fair Food Company was founded in 2012 and is basedin Chicago, IL. | $10M | Series C | Jun 29, 2017 |  |
| Evolve Biosystems | Evolve Biosystems is a biotechnology company that specializes in providing microbiome-based products designed to develop, restore, and maintain. The company's platform focuses on solving the gut dysbiosis throughout the human life cycle as well as in various animal species, enabling physicians to maintain the healthy gut microbiome in newborninfants with a consumer-directed home use product, and a hospital-based neonatal ICU product. | $20M | Series B | May 30, 2017 |  |
| Back to the Roots | Back to the Roots offers gardening kits to grow organic and gourmet mushrooms at homes. Founded in 2009 by Alejandro Velez and Nikhil Arora as a 100% sustainable urban mushroom farm, BTTR has transformed into a company focused on bringing sustainable grow-at-home products into households. Their Grow-at-Home Mushroom Garden is completely indoors andcan grow up to 1lb of oyster mushrooms in as little as 10 days. They provide a simple, eco-friendly, and quick way to have fresh oyster mushrooms right in the kitchen. | $10M | Series A | Apr 06, 2016 |  |

9 of 9 investments shown.

## Co-investors
- [Collaborative Fund](https://shizune.co/investors/profile/collaborative-fund) — VC Fund, 3 deals together
- [iSelect Fund](https://shizune.co/investors/profile/iselectfund) — VC Fund, 3 deals together
- [Skyviews Life Science](https://shizune.co/investors/profile/skyviews-life-science) — VC Fund, 3 deals together
- [Alpha Edison](https://shizune.co/investors/profile/alpha-edison) — VC Fund, 2 deals together
- [Seventure Partners](https://shizune.co/investors/profile/seventure-partners) — VC Fund, 2 deals together
- [Anthos Capital](https://shizune.co/investors/profile/anthos-capital) — VC Fund, 1 deal together

## About Acre Venture Partners

VC Fund · Santa Monica, United States

Driven by a mission to redefine food, Acre invests in companies creating systemic change in the food system to address the growing problems of human and environmental health. Acre makes venture-stage investments in highly disruptive platform businesses across the food value chain, with a particular focus on the agriculture, food tech, and consumerverticals. Taken together, these investments have the ability to form the foundation of an integrated new approach to food system evolution.

5 contacts available at Acre Venture Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Alex Bondar | Partner | https://shizune.co/investors/profile/alex-bondar-26af |
| Gareth Asten | Co-Founder and Managing Partner | https://shizune.co/investors/profile/gareth-asten |
| Samuel Kass | Partner | https://shizune.co/investors/profile/sam-kass |
| Jeffrey Dunn | Co-Founder | https://shizune.co/investors/profile/jeffrey-dunn-80bb |
| Lucas Mann | Co-Founder and Managing Partner | https://shizune.co/investors/profile/lucas-mann |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Gareth Asten invest in?

Gareth Asten invests primarily in Health Care, Biotechnology and Food and Beverage startups, most often at Series A and Series C stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Gareth Asten last invest?

The most recent investment recorded for Gareth Asten closed in Dec 2024. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co